CVE-2026-62223
HIGHOpenClaw before 2026.5.18 contain an authorization bypass vulnerability in the device-pair approval feature that allows lower-trust callers to execute actions beyond their intended…
Description
OpenClaw before 2026.5.18 contain an authorization bypass vulnerability in the device-pair approval feature that allows lower-trust callers to execute actions beyond their intended authorization. Attackers can exploit misconfigured input paths to execute or persist unauthorized actions when the affected feature is enabled and reachable.
Detection & mitigation playbook
VulnerabilityDetect
Scan your dependency tree (package-lock.json, pnpm-lock.yaml, requirements.txt, go.sum, etc.) for the affected component. O3's reachability analysis confirms whether the vulnerable code path is actually invoked in your application, so you act on real exposure instead of every transitive match.
Remediation status
No patched version of the affected component has shipped for CVE-2026-62223 yet. Where your build allows, override or pin the dependency away from the vulnerable range, and apply any maintainer-recommended mitigation.
Mitigate without a patch
If you can't upgrade right away: gate or disable the affected feature, validate untrusted input at the boundary, and avoid passing attacker-controlled data into the vulnerable path. O3's runtime protection blocks exploitation in production as an interim safeguard until the upgrade lands.
How O3 protects you
O3 pinpoints whether CVE-2026-62223 is reachable in your code and exactly where to fix it, then blocks exploitation in production at runtime until the patched version is deployed.
Tailored to CVE-2026-62223. Runtime protection reduces exposure until a permanent patch is applied and verified — it complements patching, it doesn't replace it.
Frequently Asked Questions
Is CVE-2026-62223 in your dependencies?
O3 detects CVE-2026-62223 across dependencies and uses function-level reachability to confirm whether the vulnerable code path is actually reachable — not just present. No false positives.